For the first time in history, a company has demonstrated an effective treatment for Huntington’s disease.
Aescap’s Calliditas Therapeutics received a takeover bid from Asahi Kasei: 83% premium
Japan’s Asahi Kasei Corp. announced that it intends to buy Calliditas Therapeutics at a premium of 83%. Yesterday, Calliditas closed at SEK 113,6. Asahi Kasei’s offer is SEK 208.
Aescap’s Fusion Pharmaceuticals acquired by AstraZeneca for 97% premium
AstraZeneca announced that it has come to an agreement to acquire Aescap Life Sciences portfolio company Fusion Pharmaceuticals for $ 21 and a CVR (Contingent value right) of $ 3 per share.
4D Molecular Therapeutics up 85% on good news for patients with macular degeneration
Aescap portfolio company 4DMT saw its share price increase by 85% yesterday after it announced positive results from its clinical trial for a gene therapy treatment of a form of macular degeneration (Wet AMD).
Opportunities & threats in biotech
The biotech sector has been going through some heavy turmoil since the start of the Covid-19 epidemic. Nonetheless, with the sector being back on track but still being seriously undervalued compared to other sectors, it is a promising sector for investors again. Read why!
First ‘gene-editing’ therapy approved in US and UK
Today, the FDA approved the world’s first ‘gene-editing’ therapy, Casgevy. This treatment for sickle cell disease (SCD) is based on the 2020 Nobel Prize-winning CRISPR/Cas9 technology and is developed by Aescap portfolio companies Crispr and Vertex
Ionis – positive phase 3 study Olezarsen
Aescap portfolio company Ionis announced today that its medicine candidate Olezarsen has shown a statistically significant reduction in triglyceride levels in a phase 3 clinical study.
Rocket Pharmaceuticals up 39% on good news for Danon patients
Aescap portfolio company Rocket Pharmaceuticals yesterday went up 39% after it came to an agreement with the FDA that it only needs to enroll 12 patients in a pivotal clinical trial with their gene therapy for a fatal heart disease.
Biotech, to time with a good feeling
Promising undervalued biotech companies offer an excellent opportunity for significant future returns. Waiting until the sector is back in the spotlight often results in a missed opportunity. As share prices will have risen by then.
Argenx Share Price closed 31% higher upon Positive Trial Data for CIDP
Today Argenx, an Aescap Life Sciences company, has announced positive results for its final clinical trial in patients diagnosed with CIDP (chronic inflammatory demyelinating polyneuropathy).